PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma

The relative contributions of the p53 and pRb pathways in oncogene-induced melanocyte senescence

(2016) Sebastian Haferkamp et al.   Aging-US

Inositol 5-phosphatases: insights from the Lowe syndrome protein OCRL

(2012) Michelle Pirruccello et al.   TRENDS IN BIOCHEMICAL SCIENCES

Hard Times for Oncogenic BRAF-Expressing Melanoma Cells

(2011) Miles D. Houslay   CANCER CELL

Mutant BRAF Melanomas—Dependence and Resistance

(2011) Poulikos I. Poulikakos et al.   CANCER CELL

Decreased Expression and Androgen Regulation of the Tumor Suppressor Gene INPP4B in Prostate Cancer

(2011) Myles C. Hodgson et al.   CANCER RESEARCH

PTEN Level in Tumor Suppression: How Much Is Too Little?

(2011) A. Carracedo et al.   CANCER RESEARCH

PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression

(2011) K. H. T. Paraiso et al.   CANCER RESEARCH

In Vivo Identification of Tumor- Suppressive PTEN ceRNAs in an Oncogenic BRAF-Induced Mouse Model of Melanoma

(2011) Florian A. Karreth et al.   CELL

SHIP2 multiple functions: A balance between a negative control of PtdIns(3,4,5)P3level, a positive control of PtdIns(3,4)P2production, and intrinsic docking properties

(2011) Christophe Erneux et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

BRAF targeted therapy changes the treatment paradigm in melanoma

(2011) Antoni Ribas et al.   Nature Reviews Clinical Oncology

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ets-1 mediates upregulation of Mcl-1 downstream of XBP-1 in human melanoma cells upon ER stress

(2011) L Dong et al.   ONCOGENE

MicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma

(2011) L. Jin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The role of Sp1 and Sp3 in normal and cancer cell biology

(2010) Lin Li et al.   ANNALS OF ANATOMY-ANATOMISCHER ANZEIGER

MEK-Independent Survival of B-RAFV600E Melanoma Cells Selected for Resistance to Apoptosis Induced by the RAF Inhibitor PLX4720

(2010) C. C. Jiang et al.   CLINICAL CANCER RESEARCH

The PI3K Pathway As Drug Target in Human Cancer

(2010) Kevin D. Courtney et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular circuits of solid tumors: prognostic and predictive tools for bedside use

(2010) Charles Ferté et al.   Nature Reviews Clinical Oncology

Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects

(2010) G M Marshall et al.   ONCOGENE

Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers

(2010) C. G. Fedele et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Evidence that Inositol Polyphosphate 4-Phosphatase Type II Is a Tumor Suppressor that Inhibits PI3K Signaling

(2009) Christina Gewinner et al.   CANCER CELL

Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma

(2009) M. A. Davies et al.   CLINICAL CANCER RESEARCH

PIKKing on PKB: regulation of PKB activity by phosphorylation

(2009) Lana Bozulic et al.   CURRENT OPINION IN CELL BIOLOGY

Expression of glucose-regulated stress protein GRP78 is related to progression of melanoma

(2009) Liquing Zhuang et al.   HISTOPATHOLOGY

Understanding Melanoma Signaling Networks as the Basis for Molecular Targeted Therapy

(2009) Keiran S.M. Smalley   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Requirement of Phosphatidylinositol(3,4,5)Trisphosphate in Phosphatidylinositol 3-Kinase-Induced Oncogenic Transformation

(2009) A. Denley et al.   MOLECULAR CANCER RESEARCH

BrafV600E cooperates with Pten loss to induce metastatic melanoma

(2009) David Dankort et al.   NATURE GENETICS

The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma

(2009) SubbaRao V. Madhunapantula et al.   Pigment Cell & Melanoma Research

Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy

(2008) W Weichert et al.   BRITISH JOURNAL OF CANCER

Akt3 and Mutant V600EB-Raf Cooperate to Promote Early Melanoma Development

(2008) M. Cheung et al.   CANCER RESEARCH

Statins Increase p21 through Inhibition of Histone Deacetylase Activity and Release of Promoter-Associated HDAC1/2

(2008) Y.-C. Lin et al.   CANCER RESEARCH

Multiplexed Assays for Detection of Mutations in PIK3CA

(2008) R. E. Board et al.   CLINICAL CHEMISTRY

PI3K/Akt: getting it right matters

(2008) T F Franke   ONCOGENE

PI(3,4,5)P3 and PI(3,4)P2 levels correlate with PKB/akt phosphorylation at Thr308 and Ser473, respectively; PI(3,4)P2 levels determine PKB activity

(2007) Kewei Ma et al.   CELLULAR SIGNALLING